Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

Tarlatamab is a first-in-class immunotherapy ... in the best-selling list for more restricted indications. SEL-212 from Sobi ...

Merck & Co's Keytruda cancer immunotherapy is set to become the ... the novel oral anticoagulant will be the second best selling drug in the top 10, with annual sales of $18.7 billion by 2025 ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability ...